

Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following categories best describes the mechanism of action of the novel agent zanidatamab?
 - a. Antibody-drug conjugate
 - b. Bispecific antibody**
 - c. Tyrosine kinase inhibitor
 - d. Vaccine

2. Rates of HER2 positivity are least prevalent in which of the following gynecologic cancers?
 - a. Uterine cancer
 - b. Ovarian cancer
 - c. Endometrial cancer
 - d. Cervical cancer**

3. Which of the following gynecologic cancers exhibited the greatest overall response rate (ORR) to T-DXd in the Phase II DESTINY-PanTumor02 trial?
 - a. Cervical
 - b. Endometrial**
 - c. Ovarian
 - d. ORRs were equivalent among these histological subtypes

4. Which of the following Grade 3 or higher treatment-related adverse events was most prevalent in patients who received T-DXd on the Phase II DESTINY-PanTumor02 study?
 - a. Alopecia
 - b. Anemia
 - c. Diarrhea
 - d. Neutropenia**
 - e. Thrombocytopenia

5. Which statement best characterizes the incidence of drug-related interstitial lung disease (ILD) observed with T-DXd in the Phase II DESTINY-PanTumor02 trial?
 - a. Drug-related ILD was mostly Grade 1/2**
 - b. The rate of Grade 5 drug-related ILD was approximately 5%
 - c. Drug-related ILD was mostly Grade 3/4